Antipsychotic Drug Use and the Risk of Seizures: Follow-up Study with a Nested Case–Control Analysis

Bloechliger, Marlene; Rüegg, Stephan; Jick, Susan S.; Meier, Christoph; Bodmer, Michael

doi:10.1007/s40263-015-0262-y

Cited by 51 publications

(30 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, zonisamide, an antiepileptic drug with dopaminergic effect, was reported to have beneficial effect in motor dysfunction and fluctuation in PD . On the contrary, antipsychotic drugs that reduce dopaminergic transmission have been associated with seizures . Thus, further research on the potential association between dopamine and epileptic seizures is warranted.…”

Section: Discussionmentioning

confidence: 99%

Parkinson disease and the risk of epileptic seizures

Gruntz

Bloechliger

Becker

et al. 2018

Annals of Neurology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Parkinson disease and the risk of epileptic seizures

Gruntz

Bloechliger

Becker

et al. 2018

Annals of Neurology

Self Cite

View full text Add to dashboard Cite

show abstract

“…This an important gap in the evidence. Primary-care data has been used recently in long term follow up studies of psychosis treatment [42–49], however, none addressed APP and its consequences.…”

Section: Discussionmentioning

confidence: 99%

Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews

et al. 2018

View full text Add to dashboard Cite

BackgroundThere is conflicting evidence on the association between antipsychotic polypharmacy and metabolic syndrome in schizophrenia. We conducted a review of published systematic reviews to evaluate evidence on the association between metabolic syndrome (diabetes, hypertension, and hyperlipidaemia) and exposure to antipsychotic polypharmacy in schizophrenia.MethodsWe searched five electronic databases, complemented by reference screening, to find systematic reviews that investigated the association of antipsychotic polypharmacy in schizophrenia with hypertension, diabetes, or hyperlipidaemia. Selection of reviews, data extraction and review quality were conducted independently by two people and disagreements resolved by discussion. Results were synthesised narratively.ResultsWe included 12 systematic reviews, which reported heterogeneous results, mostly with narrative syntheses and without pooled data. The evidence was rated as low quality. There was some indication of a possible protective effect of drug combinations including aripiprazole for diabetes and hyperlipidaemias, compared to other combinations and/or monotherapy. Only one review reported the association between APP and hypertension. The most frequently reported combinations of medication included clozapine, possibly representing a sample of patients with treatment resistant illness. No included review reported results separately by setting (primary or secondary care).ConclusionsFurther robust studies are needed to elucidate the possible protective effect of aripiprazole. Long-term prospective studies are required for accurate appraisal of diabetes risk, hypertension and hyperlipidaemia in patients exposed to antipsychotic polypharmacy.Electronic supplementary materialThe online version of this article (10.1186/s12888-018-1848-y) contains supplementary material, which is available to authorized users.

show abstract

“…It may induce weight gain, even though lesser than risperidone and olanzapine [23]. Furthermore, it may lower the seizure threshold [26].…”

Section: Adverse Effectsmentioning

confidence: 99%

An update of safety of clinically used atypical antipsychotics

Orsolini

Tomasetti

Valchera

et al. 2016

Expert Opinion on Drug Safety

117

View full text Add to dashboard Cite

A critical issue in the treatment with atypical APs is represented by their metabolic side effect profile (e.g. weight gain, lipid and glycaemic imbalance, risk of diabetes mellitus and diabetic ketoacidosis) which may limit their use in particular clinical samples. Electrolyte imbalance, ECG abnormalities and cardiovascular adverse effects may recommend a careful baseline and periodic assessments.

show abstract

Antipsychotic Drug Use and the Risk of Seizures: Follow-up Study with a Nested Case–Control Analysis

Cited by 51 publications

References 31 publications

Parkinson disease and the risk of epileptic seizures

Parkinson disease and the risk of epileptic seizures

Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews

An update of safety of clinically used atypical antipsychotics

Contact Info

Product

Resources

About